Search research articles
Contact Us
Filters
Showing results (541-550 of 703) with videos related to
Page
of 71
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
October 23, 2018
Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection
Martin Tio, Rajat Rai, Ogochukwu M Ezeoke, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 30, 2019
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma
Y J L Jansen, E A Rozeman, R Mason, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 24, 2015
Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors
Ravi K Amaravadi, Kathryn E Hamilton, Xiaohong Ma, et al.
Nature Communications
|
October 3, 2023
Uncovering the complex relationship between balding, testosterone and skin cancers in men
Jue-Sheng Ong, Mathias Seviiri, Jean Claude Dusingize, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 11, 2020
Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy<sup>☆</sup>
C N Owen, A N Shoushtari, D Chauhan, et al.
Journal for Immunotherapy of Cancer
|
December 2, 2020
Comprehensive analysis of cutaneous and uveal melanoma liver metastases
Esmee P Hoefsmit, Elisa A Rozeman, Trieu My Van, et al.
The New England Journal of Medicine
|
June 6, 2019
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
Caroline Robert, Jean J Grob, Daniil Stroyakovskiy, et al.
The Lancet. Oncology
|
August 2, 2021
Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' reply
Ines Pires da Silva, Tasnia Ahmed, Irene L M Reijers, et al.
Nature
|
January 11, 2018
High response rate to PD-1 blockade in desmoplastic melanomas
Zeynep Eroglu, Jesse M Zaretsky, Siwen Hu-Lieskovan, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 6, 2022
Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study
Muhammad A Khattak, Jason J Luke, Georgina V Long, et al.
Page
of 71
Search research articles
Search
Showing results (541-550 of 703) with videos related to
Sort By:
Page
of 71
European Journal of Cancer (Oxford, England : 1990)
|
October 23, 2018
Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection
Martin Tio, Rajat Rai, Ogochukwu M Ezeoke, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 30, 2019
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma
Y J L Jansen, E A Rozeman, R Mason, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 24, 2015
Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors
Ravi K Amaravadi, Kathryn E Hamilton, Xiaohong Ma, et al.
Nature Communications
|
October 3, 2023
Uncovering the complex relationship between balding, testosterone and skin cancers in men
Jue-Sheng Ong, Mathias Seviiri, Jean Claude Dusingize, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 11, 2020
Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy<sup>☆</sup>
C N Owen, A N Shoushtari, D Chauhan, et al.
Journal for Immunotherapy of Cancer
|
December 2, 2020
Comprehensive analysis of cutaneous and uveal melanoma liver metastases
Esmee P Hoefsmit, Elisa A Rozeman, Trieu My Van, et al.
The New England Journal of Medicine
|
June 6, 2019
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
Caroline Robert, Jean J Grob, Daniil Stroyakovskiy, et al.
The Lancet. Oncology
|
August 2, 2021
Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' reply
Ines Pires da Silva, Tasnia Ahmed, Irene L M Reijers, et al.
Nature
|
January 11, 2018
High response rate to PD-1 blockade in desmoplastic melanomas
Zeynep Eroglu, Jesse M Zaretsky, Siwen Hu-Lieskovan, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 6, 2022
Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study
Muhammad A Khattak, Jason J Luke, Georgina V Long, et al.
Page
of 71